Genocea Biosciences Inc. buy Reibach111
Summary
This prediction ended on 10.09.18 with a price of €4.32. Massive losses of -48.00% were the result for the BUY prediction by Reibach111. Reibach111 has 50% into this predictionGenocea Biosciences (Symbol GNCA) (WKN A2PK76) is a publicly traded, clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel vaccines and immunotherapies for various infectious diseases and cancer. With a unique approach to unlocking the power of T-cells in rapid vaccine and immunotherapy discovery, the company has established a robust pipeline targeting a wide spectrum of viral, bacterial, and parasitic diseases as well as oncology indications. Notable programs include GEN-003 for genital herpes and GEN-009, an innovative and personalized neoantigen cancer vaccine. Listed on the Nasdaq stock exchange, Genocea is dedicated to improving patient outcomes through cutting-edge research, expertise in immune targeting, and a strong commitment to scientific innovation.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Genocea Biosciences Inc. | - | - | - | - |
| iShares Core DAX® | -1,11 % | 0,20 % | 1,21 % | 51,83 % |
| iShares Nasdaq 100 | -4,35 % | -3,25 % | 25,87 % | 80,64 % |
| iShares Nikkei 225® | -6,79 % | -7,72 % | 50,97 % | 69,24 % |
| iShares S&P 500 | -1,79 % | 0,99 % | 21,07 % | 67,42 % |
Comments by Reibach111 for this prediction
In the thread Genocea Biosciences Inc. diskutieren
Reibach111 stimmt dem Crowdsentiment von 'Buy' zu
Reibach111 stimmt am 08.03.2018 dem Buy-Crowdsentiment mit dem Kursziel 3.0$ zu.
Stopped prediction by Reibach111 for Genocea Biosciences Inc.
Genocea Biosciences Inc.
13.03.19
03.06.19
03.06.19
